Phase Ib Study of Immune Biomarker Modulation with Neoadjuvant Cetuximab and TLR8 Stimulation in Head and Neck Cancer to Overcome Suppressive Myeloid Signals.

doi:10.1158/1078-0432.CCR-17-0357

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Phase Ib Study of Immune Biomarker Modulation with Neoadjuvant Cetuximab and TLR8 Stimulation in Head and Neck Cancer to Overcome Suppressive Myeloid Signals.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Jan 2018

Shayan Gulidanna, Kansy Benjamin A, Gibson Sandra P, Srivastava Raghvendra M, Bryan James Kyle, Bauman Julie E, Ohr James, Kim Seungwon, Duvvuri Umamaheswar, Clump David A, Heron Dwight E, Johnson Jonas T, Hershberg Robert M, Ferris Robert L

Abstract excerpt

Purpose: The response rate of patients with head and neck squamous cell carcinoma (HNSCC) to cetuximab therapy is only 15% to 20%, despite frequent EGFR overexpression. Because immunosuppression is common in HNSCC, we hypothesized that adding a proinflammatory TLR8 agonist to cetuximab therapy might result in enhanced T-lymphocyte stimulation and anti-EGFR-specific priming.Experimental Design: Fourteen patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Immunological

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cetuximab

Share to Immunomodulation

Share to Inflammation Mediators

Share to Lymphocytes, Tumor-Infiltrating

Share to Myeloid Cells

Share to Neoadjuvant Therapy

Share to Toll-Like Receptor 8

Source

Open in PubMed Open full text

Identifiers

PMID: 29061643
DOI: 10.1158/1078-0432.CCR-17-0357
PMCID: PMC5754237

Genes

EGFR
TLR8
TIGIT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phase Ib Study of Immune Biomarker Modulation with Neoadjuvant Cetuximab and TLR8 Stimulation in Head and Neck Cancer to Overcome Suppressive Myeloid Signals.PMID 29061643Read ↗

Modulating Tumor-Associated Macrophages through CSF1R Inhibition: A Potential Therapeutic Strategy for HNSCCSemantic proximity Read ↗

Dendritic cell effector mechanisms and tumor immune microenvironment infiltration define TLR8 modulation and PD-1 blockadeSemantic proximity Read ↗

CD137 Stimulation Enhances Cetuximab-Induced Natural Killer: Dendritic Cell Priming of Antitumor T-Cell Immunity in Patients with Head and Neck Cancer.Semantic proximity Read ↗

Cooperative tumor inhibition by CpG-oligodeoxynucleotide and cyclic dinucleotide in head and neck cancer involves T helper cytokine and macrophage phenotype reprogramming.Semantic proximity Read ↗

Response and recurrence correlates in individuals treated with neoadjuvant anti-PD-1 therapy for resectable oral cavity squamous cell carcinoma.Semantic proximity Read ↗

Epigenetic modulation of immunotherapy and implications in head and neck cancerSemantic proximity Read ↗

Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients.Semantic proximity Read ↗

Trametinib Drives T-cell-Dependent Control of KRAS-Mutated Tumors by Inhibiting Pathological Myelopoiesis.Semantic proximity Read ↗

Synergistic Anti-Tumor Efficacy Achieved by Reversing Drug Resistance through the Regulation of the Tumor Immune Microenvironment with IL-12 and Osimertinib Combination TherapySemantic proximity Read ↗

Immunomodulatory effects in a phase II study of lenalidomide combined with cetuximab in refractory KRAS-mutant metastatic colorectal cancer patients.Semantic proximity Read ↗

STAT1-Induced HLA Class I Upregulation Enhances Immunogenicity and Clinical Response to Anti-EGFR mAb Cetuximab Therapy in HNC Patients.Semantic proximity Read ↗

TLR8 ligation induces apoptosis of monocytic myeloid-derived suppressor cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.